TY - JOUR
T1 - Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies
AU - Vogt, Anne Cathrine S.
AU - Jörg, Lukas
AU - Martina, Byron
AU - Krenger, Pascal S.
AU - Chang, Xinyue
AU - Zeltins, Andris
AU - Vogel, Monique
AU - Mohsen, Mona O.
AU - Bachmann, Martin F.
N1 - Publisher Copyright:
Copyright © 2022 Vogt, Jörg, Martina, Krenger, Chang, Zeltins, Vogel, Mohsen and Bachmann.
PY - 2022/6/16
Y1 - 2022/6/16
N2 - mRNA based vaccines against COVID-19 have proven most successful at keeping SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for COVID-19 to maintain antibody responses for the control of continuously emerging SARS-CoV-2 variants of concern (VoCs) and to overcome other obstacles such as supply shortage, costs and reduced safety issues or inadequatly induced immune-responses. In this study, we investigated the antibody responses induced by heterologous prime-boost with vaccines based on mRNA and virus-like particles (VLPs). The VLP-based mCuMVTT-RBM vaccine candidate and the approved mRNA-1273 vaccine were used for this purpose. We find that homologous prime boost regimens with either mRNA or VLP induced high levels of high avidity antibodies. Optimal antibody responses were, however, induced by heterologous regimens both for priming with mRNA and boosting with VLP and vice versa, priming with VLP and boosting with mRNA. Thus, heterologous prime boost strategies may be able to optimize efficacy and economics of novel vaccine strategies.
AB - mRNA based vaccines against COVID-19 have proven most successful at keeping SARS-CoV-2 pandemic at bay in many countries. Recently, there is an increased interest in heterologous prime-boost vaccination strategies for COVID-19 to maintain antibody responses for the control of continuously emerging SARS-CoV-2 variants of concern (VoCs) and to overcome other obstacles such as supply shortage, costs and reduced safety issues or inadequatly induced immune-responses. In this study, we investigated the antibody responses induced by heterologous prime-boost with vaccines based on mRNA and virus-like particles (VLPs). The VLP-based mCuMVTT-RBM vaccine candidate and the approved mRNA-1273 vaccine were used for this purpose. We find that homologous prime boost regimens with either mRNA or VLP induced high levels of high avidity antibodies. Optimal antibody responses were, however, induced by heterologous regimens both for priming with mRNA and boosting with VLP and vice versa, priming with VLP and boosting with mRNA. Thus, heterologous prime boost strategies may be able to optimize efficacy and economics of novel vaccine strategies.
UR - https://www.scopus.com/pages/publications/85133244475
U2 - 10.3389/fimmu.2022.864718
DO - 10.3389/fimmu.2022.864718
M3 - Article
C2 - 35784292
AN - SCOPUS:85133244475
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 864718
ER -
